Connecting 80+ EHS experts in pharma and biopharma on the West coast, this year's meeting will address the challenges of ...

Stoke Therapeutics advances RNA-based therapies for rare diseases like Dravet Syndrome.

Is chaos in US health policy creating new global opportunities? With major leadership and policy shake-ups the US healthcare ...

The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was ...

The global Oligonucleotide Synthesis Market is valued at USD 7.78 Billion in 2024 and is projected to reach a value of USD 21 ...

The pivotal trial for Neurogene's Rett syndrome gene therapy makes use of baseline controls and a rigorous endpoint that ...

Biogen has emerged as a front-runner at the Cannes Lions, snagging four spots on the Pharma shortlist for its work on Friedreich’s ataxia.

Biogen plans to advance an experimental treatment for the neuromuscular disease spinal muscular atrophy, or SMA, into registrational studies following encouraging results from an early-stage trial.

Biogen on Monday said the phase 3 study will evaluate the efficacy and safety of felzartamab compared to the immunosuppressive drug tacrolimus in adults with PMN, with a readout expected in 2029.